Pharmaceutical - Novo Nordisk, Sanofi


Current filters:

Novo NordiskSanofi

Popular Filters

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar

Novo Nordisk and Sanofi best positioned in diabetes market, says Morningstar


Demographics favor the continued strong growth in the diabetes care market, and independent investment…

DiabetesEli LillyFinancialMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Geropharm to invest $45 million in Russian insulin production

Geropharm to invest $45 million in Russian insulin production


Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for…

DiabetesEli LillyEuropeFinancialGeropharmNovo NordiskPharmaceuticalProductionSanofi

Sanofi latest to be implicated Chinese bribery allegations


In the wake of allegations that several multinational pharma companies have engaged in unlawful marketing…

Asia-PacificLegalLundbeckMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA


US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin


Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five…

Asia-PacificDiabetesEli LillyMarkets & MarketingNovo NordiskPharmaceuticalSanofi

News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus


Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve…

Amicus TherapeuticsAmigalDiabetesFIAspFinancialGlaxoSmithKlineHyalganIDegLiraLegalNorth AmericaNovo NordiskPharmaceuticalRare diseasesResearchSanofi

Global diabetes drugs market led by Novo Nordisk and Sanofi


The global diabetes drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

DiabetesGlobalMarkets & MarketingNovo NordiskPharmaceuticalSanofi

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus


Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

Back to top